Abstract
Alzheimer’s Disease (AD) continues to be a leading cause of death in the US. As the US aging population (ages 65+) expands, the impact will disproportionately affect vulnerable populations, e.g., Hispanic/Latinx population, due to their AD-related health disparities. Age-related regression in mitochondrial activity and ethnic-specific differences in metabolic burden could potentially explain in part the racial/ethnic distinctions in etiology that exist for AD. Oxidation of guanine (G) to 8-oxo-guanine (8oxoG) is a prevalent lesion and an indicator of oxidative stress and mitochondrial dysfunction. Damaged mtDNA (8oxoG) can serve as an important marker of age-related systemic metabolic dysfunction and upon release into peripheral circulation may exacerbate pathophysiology contributing to AD development and/or progression. Analyzing blood samples from Mexican American (MA) and non-Hispanic White (NHW) participants enrolled in the Texas Alzheimer’s Research & Care Consortium, we used blood-based measurements of 8oxoG from both buffy coat PBMCs and plasma to determine associations with population, sex, type-2 diabetes, and AD risk. Our results show that 8oxoG levels in both buffy coat and plasma were significantly associated with population, sex, years of education, and reveal a potential association with AD. Furthermore, MAs are significantly burdened by mtDNA oxidative damage in both blood fractions, which may contribute to their metabolic vulnerability to developing AD.
Introduction
Alzheimer’s disease (AD) is the most common form of dementia, characterized by symptoms of cognitive decline such as memory deficits, impaired problem-solving, difficulty communicating, and additional cerebral incompetencies1,2. This heterogenous neurodegenerative disease is commonly known for its neurotoxic pathophysiological properties including the accumulation of amyloid beta (Ab) plaques and tangles of hyperphosphorylated tau protein1–3. However, impaired mitochondrial function and chronic inflammation are frequently reported and can be considered as contributors to the observed endophenotypic manifestations of cognitive impairment (CI) likely caused by Alzheimer’s2–8. Particularly, non-Hispanic Whites (NHWs) appear to exhibit an inflammatory endophenotype4–7, while Mexican Americans (MAs) present a metabolic endophenotype5. This evidence may point to population-specific biological and environmental factors influencing CI. Importantly, current established biomarkers are invasive, expensive, and have limited accessibility (i.e., cerebral spinal fluid testing, neuroimaging). Identifying blood-based biomarkers capable of predicting disease onset and assessing disease progression (e.g., preclinical AD, mild cognitive impairment [MCI], and AD) is of great importance to understand the pathophysiological heterogeneity of AD which will inform ultimately more precise therapeutics.
Type-2 diabetes (T2D) is a considerable risk factor for AD due to its comorbid association with CI; however, the precise pathophysiological mechanisms connecting these two complex diseases are unclear. As the aging Hispanic/Latinx population is expected to exponentially increase compared to other ethnic/racial groups, the healthcare burden affecting this population is expected to worsen due to age-related diseases (e.g., AD and diabetes)1,9. It has been previously reported that the Ser(326)Cys polymorphism (rs1052133) in 8-Oxoguanine glycosylase (OGG1), an important glycosylase of the base excision repair pathway involved in the recognition and excision of 8oxoG within DNA, delays repair of oxidative DNA damage10 and is associated with T2D risk in MAs13. Recent observations suggest OGG1 regulates cellular energy metabolism and thus shapes metabolic phenotypes during high-fat diet exposure, indicating DNA damage repair may be important to metabolic health11–13. Studies by Komakula et al., and Sampath et al., revealed that functional OGG1 prevented obesity and metabolic dysfunction upon induction in response to a high-fat diet potentially via direct or indirect expression changes of PGC-1a and fatty acid oxidation 11,12. Similarly, reduced expression of PGC-1a is consistently observed in T2D patients14,15 and is linked to elevated ROS levels and decreased levels of b-oxidation enzymes16. AD disproportionately affects Hispanics/Latinos compared to NHWs; this is thought to be due to the increased prevalence of metabolic syndrome, obesity, cardiovascular health risks, and diabetes9,17,18. These observations combined with our previous data indicating MAs have elevated levels of oxidative damage compared to NHWs, leads us to the premise that mitochondrial health may hold greater biological importance in the development of age-related disease for individuals with Hispanic/Latinx ancestry19.
Compared to the nuclear genome, mitochondrial DNA is especially susceptible to oxidative damage. Elevated levels of ROS generate oxidative stress (OS) and an oxidative environment capable of oxidatively damaging important biomolecules and may cause detrimental effects in genomic coding regions20–22. Due to the low oxidation potential of guanine, the most common forms of oxidative DNA damage are: 8-oxo-7,8-dihydroguanine (8oxoG) and 8-oxo-7,8-dihydrodeoxyguanine (8oxodG)21–26. Oxidation of guanine possesses unique mutagenic properties that when left unrepaired, can perturb cellular function through several mechanisms and effect protein-DNA binding (e.g., transcription factors)21,22,25,26. Furthermore, oxidized guanine can result in missense mutations and often modify the activity of downstream products, such as RNAs and proteins20–22, 25,27. Due to the nature of the mitochondrial genome within various cell types and tissues, oxidative DNA damage will influence distinctive pathophysiological outcomes in tissue with differing function depending on the location, metabolic activity, and enzymatic processes 26. In response to mitochondrial damage there are QC processes at the cellular, organellar, and molecular level that are employed to preserve mitochondrial integrity28. As mitochondria work in dynamic networks, fusion with nearby mitochondria can recover function; however, excessive damage undermines fusion activity resulting in fragmented mitochondria that are removed through mitophagy and/or apoptosis28.
Growing evidence implicates oxidative DNA damage as a primary and secondary contributor to pathology observed in the AD continuum29–32. Recent evidence from our lab analyzing blood-based indices of mtDNA copy number (CN) and cell-free mtDNA (cf-mtDNA) to investigate mitochondrial dysfunction in complex disease (T2D and CI) among MAs showed that mtDNA CN was significantly associated with both T2D and CI18. Also, cf-mtDNA was found to be higher in individuals with either disease, reaching significant levels in individuals with both diseases compared to normal controls18. Cellular mtDNA CN is an indicator of mitochondrial biogenesis and cellular energetics18,33, which can be used as a measurement of mitochondrial health34.
Circulating cell-free mitochondrial DNA (ccf-mtDNA) has been increasingly studied as a biomarker for systemic inflammation during cellular stress or apoptosis. In this process, mtDNA fragments are released by cells into the bloodstream, where their bacterial origins cause them to be recognized as a damage associated molecular pattern (DAMP), thereby eliciting an inflammatory response through activation of innate immune cells18, 34–36. There are numerous studies assessing ccf-mtDNA as a clinical diagnostic and predictive biomarker (e.g., in affective disorders, and mitochondrial, autoimmune, neurological, and cardiovascular diseases) 34,35, 37–40, and accumulating evidence indicates that mitochondrial dysfunction and mtDNA damage are correlated with disease severity and levels of ccf-mtDNA35,39.
Our mtDNA CN and cf-mtDNA data can be considered as a proxy for our more recent data evaluating mitochondrial 8oxoG variant load since it does not capture if mutation has occurred. More recently in a similar population-based cohort, we discovered that mtDNA variants indicative of 8oxoG were significantly elevated in MAs compared to NHWs and was associated with sex, education, and suggestive for cognitive function19. Correspondingly, Miller, et al., revealed AD neurons compared to age-matched controls had significantly elevated levels of somatic single nucleotide variants (sSNVs) than anticipated when considering sSNVs are known to increase with age32, and the distribution of the variants are presumed to occur secondary to developing disease pathology32. Further analysis established potential mechanisms of oxidative DNA damage developed from 8oxoG (nonsynonymous mutations, e.g., C > A) that might contribute to the significant increase of sSNVs in AD, especially in protein-coding genes32. The increased substitution mutations could be a result of increased ROS and OS, a common feature observed in AD brains, the CNS, and periphery, which can contribute to inflammation and mitochondrial dysfunction32,41. This accumulating evidence may point at a mutational signature important to AD pathophysiology influencing the differing endophenotype reported in AD, particularly of those with different mitochondrial capacity, metabolic health, and comorbidity risk such as those linked to ethnic/racial AD health disparities.
Oxidative transversion substitution mutations may be associated with increased mitochondrial dysfunction due to impaired mitochondrial capacity, metabolic health, and/or lifestyle affecting mitochondrial health, and contribute to the continuous progression of AD until a clinical endpoint, death. In this current study, our objective was to use a blood-based measurement of 8oxoG sSNVs as an indicator of impaired mitochondrial function to investigate the role of mitochondria in pathophysiology of complex disease by (1) characterizing associations to population and sex, (2) highlighting burdened genomic regions that influence mitochondrial function, and (3) determining differences in buffy coat or plasma on evaluating AD risk and/or endophenotype.
Results
Descriptive statistics for the cohort analyzed for cellular mitochondrial 8oxoG variants are displayed in Table 1. As anticipated, MMSE, CDR sum, and years of education in both populations had significantly different means based on cognitive status. Age significantly differed in MAs between cognitive groups and years of education was lower compared to NHWs.
Table 1.
Descriptive statistics of NHW and MA participants categorized by population and cognitive phenotype in the Texas Alzheimer’s Research and Care Consortium for buffy coat mitochondrial DNA oxidative mutational load.
| NC | MCI | AD | P-valuea | |
|---|---|---|---|---|
| Total Number of Subjects | 328 | 127 | 104 | |
| Non-Hispanic Whites | 153 | 43 | 64 | |
| Age [CI] | 70.39 ± 1.178 | 71.35 ± 1.421 | 71.70 ± 1.056 | 0.338 |
| Sex (F) [n, %] | 78, 50.98% | 21, 48.84% | 29, 45.31% | 0.747 |
| Mini Mental State Exam (MMSE) [CI] | 29.11 ± 0.1759 | 27.63 ± 0.6223 | 21.53 ± 1.413 | < 0.001b |
| Clinical Dementia Rating (CDR) Sum [CI] | 0.007 ± 0.009 | 1.163 ± 0.2181 | 5.344 ± 0.8515 | < 0.001c |
| Years of Education [CI] | 16.07 ± 0.4063 | 14.56 ± 0.6597 | 15.11 ± 0.7524 | 0.001d |
| BMI kg/m^2 [CI] | 27.331 ± 1.150 | 27.272 ± 2.328 | 27.394 ± 1.062 | 0.996 |
| Diabetes (Y) [n, %] | 59, 38.56% | 18, 41.86% | 22, 34.38% | 0.723 |
| Hypercholesterolemia (Y) [n, %] | 90, 58.82% | 26, 60.47% | 50, 78.13% | 0.023 |
| Hyperlipidemia (Y) [n, %] | 56, 36.60% | 15, 34.88% | 39, 60.94% | 0.002 |
| Hypertension (Y) [n, %] | 100, 65.36% | 31, 72.09% | 44, 68.75% | 0.680 |
| Obesity (Y) [n, %] | 27, 17.65% | 8, 18.69% | 10, 15.63% | 0.910 |
| Depression (Y) [n, %] | 12, 7.84% | 6, 13.95% | 17, 26.56% | 0.001 |
| Tobacco Abuse (Y) [n, %] | 51, 33.33% | 18, 41.86% | 28, 43.75% | 0.279 |
| Alcohol Abuse (Y) [n, %] | 3, 1.96% | 5, 11.63% | 3, 4.69% | 0.020 |
| Mexican Americans | 175 | 84 | 40 | |
| Age [CI] | 67.62 ± 0.8156 | 69.88 ± 1.691 | 73.37 ± 2.485 | < 0.001e |
| Sex (F) [n, %] | 99, 56.57% | 40, 47.62% | 24, 60.00% | 0.302 |
| Mini Mental State Exam (MMSE) [CI] | 28.14 ± 0.2889 | 24.93 ± 1.140 | 19.87 ± 1.860 | < 0.001f |
| Clinical Dementia Rating (CDR) Sum [CI] | 0.006 ± 7.89710−3 | 1.113 ± 0.2261 | 5.737 ± 1.183 | < 0.001g |
| Years of Education [CI] | 11.05 ± 0.6598 | 8.77 ± 1.664 | 9.75 ± 1.547 | 0.002h |
| BMI kg/m^2 [CI] | 30.917 ± 0.9992 | 31.295 ± 2.228 | 28.717 ± 1.651 | 0.116 |
| Diabetes (Y) [n, %] | 79, 45.14% | 32, 38.10% | 19, 47.50% | 0.484 |
| Hypercholesterolemia (Y) [n, %] | 103, 58.86% | 52, 61.90% | 23, 57.50% | 0.862 |
| Hyperlipidemia (Y) [n, %] | 89, 50.86% | 35, 41.67% | 12, 30.00% | 0.120 |
| Hypertension (Y) [n, %] | 120, 68.57% | 63, 75.00% | 28, 70.00% | 0.567 |
| Obesity (Y) [n, %] | 84, 48.00% | 38, 45.24% | 8, 20.00% | 0.005 |
| Depression (Y) [n, %] | 19, 10.86% | 29, 34.52% | 15, 37.50% | <0.001 |
| Tobacco Abuse (Y) [n, %] | 82, 46.86% | 39, 46.43% | 18, 45.00% | 0.978 |
| Alcohol Abuse (Y) [n, %] | 6, 3.43% | 0, 0.00% | 2, 5.00% | 0.172 |
The mean difference is significant at 0.05
NC vs. MCI 0.016, NC vs. AD <0.001, MCI vs. AD <0.001
NC vs. MCI <0.001, NC vs. AD <0.001, MCI vs. AD <0.001
NC vs. MCI 0.003, NC vs. AD 0.042, MCI vs. AD 0.542
NC vs. MCI 0.028, NC vs. AD <0.001, MCI vs. AD 0.017
NC vs. MCI <0.001, NC vs. AD <0.001, MCI vs. AD <0.001
NC vs. MCI <0.001, NC vs. AD <0.001, MCI vs. AD <0.001
NC vs. MCI 0.001, NC vs. AD 0.273, MCI vs. AD 0.540
Directly genotyped and imputed APOE frequencies for each population is shown in Supplementary Table 1. Genotype frequencies for APOE and OGG1 by cognitive status in each population are shown in Supplementary Table 2. Hardy-Weinberg proportions for APOE and OGG1 in both populations separately and together indicates the genotype frequencies are in Hardy-Weinberg equilibrium and both the observed and expected genotype frequencies are not significantly different (Supplementary Tables 3 and 4).
Evaluation of 8oxoG Variant Count in the Buffy Coat of MA and NHW TARCC Participants
In the MA population 8oxoG variant count was significantly reduced for subjects reporting depression compared to those without depression; mean = 6.548 and 7.704, respectively (Supplemental Fig. 1). Tobacco abuse demonstrated an approach for significance in association with 8oxoG demonstrating a higher variant load compared to non-smokers in MAs; mean = 7.935 and 7.048, respectively (Supplemental Fig. 2). These trends were not observed in the NHW cohort.
Multiple linear regression model predictions in the whole cohort were performed to assess the associations with 8oxoG and to determine if there are predictive interactions. Sex regarding females (p = 0.0007), years of education (p = 0.0055), BMI (p = 0.0288), and tobacco abuse (p = 0.0086) were significantly associated with 8oxoG variant count, and the population-sex interaction demonstrated a significant interaction effect (p = 0.0038) (Supplementary Table 5). Further analysis of 8oxoG variant count in both population and sex via two-way ANOVA indicates population is significantly associated (p < 0.0001), while sex was marginally significant (p = 0.0922).
In the subsequent multiple linear regression model, a diabetes × cognition interaction was evaluated and showed a significant association with population (p < 0.0001), sex (p = 0.0429), years of education (p = 0.0109), BMI (p = 0.0254), and tobacco abuse (p = 0.0155); although the interaction effect was not significant (Supplementary Table 6). Cognitive status with respect to AD displayed a suggestive association compared to controls (p = 0.0556).
Previously derived 8oxoG variant load for each subject corresponding to 8oxoG “hotspots”19 were further analyzed via multiple linear regression prediction models assessing a population × sex and years of education interaction effect, and a diabetes × cognition interaction effect was less informative than analyzing total 8oxoG variant count (Supplementary Tables 7 and 8). Population stratification lost significant statistical associations (Supplementary Tables 9 and 10) that were observed in Supplementary Tables 7 and 8.
Multiple linear regression modelling in MAs indicated that total 8oxoG was significantly associated with cognitive status, sex, years of education, and tobacco abuse (Table 2). BMI did not show significant association in MAs as compared to the regression models investigating interactive effects (Supplementary Tables 5–6). Modelling within NHWs did not demonstrate any associations (Table 3).
Table 2.
Multiple linear regression prediction model in the Mexican American population considering total cellular 8oxoG variant count. Italics and bolding indicate a p-value of significance, while italics alone indicate a p-value approaching significance.
| Variable | Coefficient | Std. Error | t-statistic | p-value |
|---|---|---|---|---|
| Constant | 5.38624 | 3.66547 | 1.469 | 0.143088 |
| Cognitive Status (with respect to AD) | 1.88775 | 0.90381 | 2.089 | 0.037847 |
| Cognitive Status (with respect to MCI) | 1.11683 | 0.71666 | 1.558 | 0.120533 |
| Sex (with respect to Male) | −2.23145 | 0.62169 | −3.589 | 0.000406 |
| Age | −0.01812 | 0.04432 | −0.409 | 0.68306 |
| Years of Education | 0.15433 | 0.06272 | 2.461 | 0.01461 |
| BMI | 0.0733 | 0.05051 | 1.451 | 0.148079 |
| Diabetes (with respect to “Yes”) | −0.97291 | 0.62086 | −1.567 | 0.118495 |
| Depression (with respect to “Yes”) | −1.4407 | 0.79867 | −1.804 | 0.072569 |
| Tobacco Abuse (with respect to “Yes”) | 1.97348 | 0.60289 | 3.273 | 0.001228 |
| APOE | 0.18362 | 0.65285 | 0.281 | 0.778769 |
| OGG1 | −0.03107 | 0.42738 | −0.073 | 0.942111 |
| R-squared | 0.1199 | p-value | 0.001776 | |
| Adjusted R-squared | 0.07743 | df | 11 and 228 | |
| F-statistic | 2.824 | Sample n | 201 |
Table 3.
Multiple linear regression prediction model in non-Hispanic Whites considering total cellular 8oxoG variant count. Italics and bolding indicate a p-value of significance, while italics alone indicate a p-value approaching significance.
| Variable | Coefficient | Std. Error | t-statistic | p-value |
|---|---|---|---|---|
| Constant | 0.42632 | 3.39267 | 0.126 | 0.9 |
| Cognitive Status (with respect to AD) | −0.1306 | 0.57357 | −0.228 | 0.82 |
| Cognitive Status (with respect to MCI) | 0.23 | 0.64941 | 0.354 | 0.724 |
| Sex (with respect to Male) | 0.60026 | 0.45481 | 1.32 | 0.189 |
| Age | 0.04559 | 0.03686 | 1.237 | 0.218 |
| Years of Education | 0.0119 | 0.08375 | 0.142 | 0.887 |
| BMI | 0.07021 | 0.04965 | 1.414 | 0.159 |
| Diabetes (with respect to “Yes”) | −0.17897 | 0.53328 | −0.336 | 0.738 |
| Depression (with respect to “Yes”) | 0.01429 | 0.64799 | 0.022 | 0.982 |
| Tobacco Abuse (with respect to “Yes”) | −0.14434 | 0.46294 | −0.312 | 0.756 |
| APOE | 0.17776 | 0.36646 | 0.485 | 0.628 |
| OGG1 | −0.28863 | 0.37952 | −0.761 | 0.448 |
| R-squared | 0.04111 | p-value | 0.7794 | |
| Adjusted R-squared | −0.02168 | df | 11 and 168 | |
| F-statistic | 0.6547 | Sample n | 180 |
Additional prediction modelling used cognitive status as a binary variable to combine the effects of AD and MCI compared to NCs and showed similar results to the models with greater resolution on cognitive status (Supplementary Tables 11–618).
Assessment of ccf-mtDNA 8oxoG Variant Count in MA and NHW TARCC Participants
The subset of participants included for the ccf-mtDNA 8oxoG variants were selected from subjects included in the buffy coat analysis to compare the blood fractions collected from the same visit (Table 4). Age, sex, and years of education were considered confounding variables for CI and were utilized with the aim to pairwise match AD with NCs to help reduce the risk of confounders influencing false associations to AD due to the smaller sample size.
Table 4.
Descriptive statistics of NHW and MA TARCC participants classified by population and cognitive phenotype for plasma (i.e., ccf) mitochondrial DNA oxidative mutational load.
| NC | AD | P-valuea | |
|---|---|---|---|
| Total Number of Subjects | 63 | 59 | |
| Non-Hispanic Whites | 33 | 32 | |
| Age [CI] | 72.30 ± 3.112 | 72.19 ± 1.913 | 0.951 |
| Sex (F) [n, %] | 19, 57.58% | 19, 58.62% | 0.883 |
| Mini Mental State Exam (MMSE) [CI] | 28.91 ± 0.4296 | 20.41 ± 2.214 | < 0.001 |
| Clinical Dementia Rating (CDR) Sum [CI] | 0.000 ± 0.000 | 5.625 ± 1.353 | < 0.001 |
| Years of Education [CI] | 14.12 ± 0.9178 | 14.13 ± 0.9549 | 0.996 |
| BMI kg/m^2 [CI] | 27.997 ± 2.291 | 27.709 ± 1.632 | 0.842 |
| Diabetes (Y) [n, %] | 15, 45.45% | 16, 50.00% | 0.714 |
| Hypercholesterolemia (Y) [n, %] | 17, 51.52% | 27, 84.38% | 0.005 |
| Hyperlipidemia (Y) [n, %] | 11, 33.33% | 24, 75.00% | < 0.001 |
| Hypertension (Y) [n, %] | 23, 69.70% | 22, 68.75% | 0.934 |
| Obesity (Y) [n, %] | 25, 75.76% | 26, 81.25% | 0.590 |
| Depression (Y) [n, %] | 6, 18.18% | 12, 37.50% | 0.082 |
| Tobacco Abuse (Y) [n, %] | 13, 39.39% | 16, 50.00% | 0.390 |
| Alcohol Abuse (Y) [n, %] | 1, 3.03% | 2, 6.25% | 0.536 |
| Mexican Americans | 30 | 27 | |
| Age [CI] | 73.23 ± 1.971 | 73.89 ± 3.184 | 0.733 |
| Sex (F) [n, %] | 17, 56.67% | 14, 51.85% | 0.716 |
| Mini Mental State Exam (MMSE) [CI] | 27.83 ± 0.6846 | 19.63 ± 2.111 | < 0.001 |
| Clinical Dementia Rating (CDR) Sum [CI] | 0.017 ± 0.03267 | 5.574 ± 1.282 | < 0.001 |
| Years of Education [CI] | 9.93 ± 1.971 | 9.63 ± 1.794 | 0.824 |
| BMI kg/m^2 [CI] | 31.06 ± 2.166 | 28.319 ± 1.8647 | 0.065 |
| Diabetes (Y) [n, %] | 12, 40.00% | 13, 48.15% | 0.536 |
| Hypercholesterolemia (Y) [n, %] | 17, 56.67% | 17, 62.96% | 0.629 |
| Hyperlipidemia (Y) [n, %] | 13, 43.33% | 8, 29.63% | 0.284 |
| Hypertension (Y) [n, %] | 21, 70.00% | 18, 66.67% | 0.787 |
| Obesity (Y) [n, %] | 17, 56.67% | 23, 85.19% | 0.019 |
| Depression (Y) [n, %] | 3, 10.00% | 11, 40.74% | 0.007 |
| Tobacco Abuse (Y) [n, %] | 12, 40.00% | 13, 48.15% | 0.536 |
| Alcohol Abuse (Y) [n, %] | 1, 3.33% | 2, 7.41 % | 0.492 |
The mean difference is significant at 0.05.
Genotype frequencies obtained and imputed for APOE in each population and genotype frequencies for APOE and OGG1 distributed by cognitive status in each population are shown (Supplementary Tables 19 and 20). Testing for Hardy-Weinberg Equilibrium for APOE and OGG1 were insignificant for the total cohort and within each population, indicating that the genotype frequencies are in equilibrium (Supplementary Tables 21 and 22).
Although our attempt to match samples based on age was unsuccessful; a Pearson’s correlation was performed to exclude age as a potential cofounder and showed age does not need to be considered a covariate in our dataset as it was not correlated with total ccf-mtDNA 8oxoG variant count (Supplementary Fig. 3).
MAs, especially females, have a greater burden in total ccf-8oxoG variant count
In the whole cohort ccf-8oxoG variant count was significantly elevated in the MA population compared to NHWs; mean = 0.8500 and 0.7160, respectively (Fig. 1). Ccf-8oxoG variant count did not significantly differ based on cognitive status or sex (Supplementary Fig. 4 and Supplementary Fig. 5). A significant population · sex interaction was not observed (Fig. 2); however, ccf-8oxoG variant count was significantly elevated in MA females compared to NHW females (mean = 0.8702 and 0.7771, respectively). Despite cognitive phenotype, MAs had an elevated 8oxoG sSNV burden compared to NHWs (Fig. 3), yet there was not a significant difference for 8oxoG variant count in each population when assessing for sex and cognitive phenotype (Fig. 4).
Figure 1.
ccf-mtDNA 8oxoG variant count is significantly elevated in the Mexican American population. a Log transformed ccf-mtDNA 8oxoG variant count grouped by population using an unpaired, two-tailed t-test (n = 122, t-statistic = 4.666, df = 120, p = < 0.0001). Error bars represent standard error of the mean. b Violin plot demonstrating distribution of 8oxoG variant count in MAs and NHWs (n= 122) with effect size and confidence interval plotted on right y-axis. Dashed lines indicate the mean and dotted lines represent the 1st and 3rd quartile. The triangle represents the difference of the means.
Figure 2.

ccf-mtDNA 8oxoG variant count is significantly higher in Mexican American females compared to non-Hispanic White females. Log transformed plasma 8oxoG variant count by population and sex was analyzed using a two-way ANOVA (n = 122, p = 0.1275, F-statistic = 2.356, df = 118). Significant p-value for MA-Female 8oxoG variant count compared to NHW-Female (p = 2.515e-005). Error bars represent standard error of the mean.
Figure 3.
ccf-mtDNA 8oxoG variant count is significantly higher in Mexican Americans compared to non-Hispanic Whites despite cognitive phenotype. Log transformed plasma 8oxoG variant count by population and cognitive status was analyzed using a two-way ANOVA with interaction terms for population-cognition (n = 122, p = 0.4434, F-statistic = 0.5916, df = 118). There is no significant population × cognition interaction. Significant source of variation was caused by population (p = <0.0001). Significant p-value for MA-NC 8oxoG variant count compared to NHW-NC (p = 0.0301) and MA-AD compared to NHW-AD (p = 0.0014). Error bars represent standard error of the mean.
Figure 4.
ccf-mtDNA 8oxoG variant count by cognitive phenotype and sex in each population. a Grouped bar graph of log transformed plasma 8oxoG variant count by cognition and sex in MAs testing for cognition × sex interaction via two-way ANOVA (n = 57, p = 0.3633, F-statistic = 0.8408, df = 53). b Grouped bar graph of log transformed plasma 8oxoG variant count by cognition and sex in NHWs testing for cognition × sex interaction via two-way ANOVA (n = 65, p = 0.6476, F-statistic = 0.2110, df = 61). Error bars represent standard error of the mean.
Results of multiple linear regression modelling of ccf-mtDNA 8oxoG variant count in the whole cohort with respect to population- sex and education interactive effects while considering APOE status as a dosage effect (i.e., no ε4 allele, one ε4 allele, two ε4 alleles) indicated a significant positive association for APOE and the population · sex interaction (Supplementary Table 23). When assessing for a diabetes × cognition interaction, a significant association between ccf-8oxoG variant count and both population and APOE was determined (Supplementary Table 24).
Additional multiple linear regression models were performed to characterize associations with 8oxoG “hotspots” in the whole cohort (Supplementary Fig. 6 and Supplementary Tables 25–26). The regression modelling for both interaction effects, population × sex and education, and diabetes × cognition in the whole cohort did not observe the same associations for 8oxoG “hotspots”, indicating these variants may not be informative in this context.
Population-specific associations to ccf-8oxoG variant count
Population stratification for the multiple linear regression models did not demonstrate any statistical significance for ccf-8oxoG count in MAs (Table 5); however, in the NHW population AD and diabetes was marginally significant (Table 6). Further, the model showed significant statistical association with sex and age, as well.
Table 5.
Multiple linear regression results for ccf-8oxoG variant count within Mexican Americans. Italics and bolding indicate a p-value of significance, while italics alone indicate a p-value approaching significance.
| Variable | Coefficient | Std. Error | t-statistic | p-value |
|---|---|---|---|---|
| Constant | 0.9416425 | 0.3160556 | 2.979 | 0.00495 |
| Cognitive Status with respect to AD | −0.0213429 | 0.0538188 | −0.397 | 0.69385 |
| Sex with respect to Male | −0.0475924 | 0.0500437 | −0.951 | 0.34745 |
| Age | −0.0003705 | 0.0033248 | −0.111 | 0.91184 |
| Years of Education | −0.0005624 | 0.0052002 | −0.108 | 0.91443 |
| BMI | −0.0017609 | 0.005286 | −0.333 | 0.74082 |
| Diabetes with respect to “Yes” | −0.0280655 | 0.0557223 | −0.504 | 0.61733 |
| Depression (with respect to “Yes”) | −0.0086758 | 0.0653148 | −0.133 | 0.89501 |
| Tobacco Abuse (with respect to “Yes”) | −0.0399383 | 0.0532798 | −0.75 | 0.458 |
| APOE | 0.0629617 | 0.061671 | 1.021 | 0.31358 |
| OGG1 | 0.0430802 | 0.0385428 | 1.118 | 0.27052 |
| R-squared | 0.1495 | p-value | 0.7312 | |
| Adjusted R-squared | −0.06859 | df | 10 and 39 | |
| F-statistic | 0.6855 | Sample n | 50 |
Table 6.
Multiple linear regression results for ccf-8oxoG variant count within non-Hispanic Whites. Italics and bolding indicate a p-value of significance, while italics alone indicate a p-value approaching significance.
| Variable | Coefficient | Std. Error | t-statistic | p-value |
|---|---|---|---|---|
| Constant | 1.115392 | 0.327981 | 3.401 | 0.00182 |
| Cognitive Status with respect to AD | −0.107136 | 0.05317 | −2.015 | 0.05237 |
| Sex with respect to Male | 0.107027 | 0.046919 | 2.281 | 0.02934 |
| Age | −0.007998 | 0.003727 | −2.146 | 0.03954 |
| Years of Education | −0.002487 | 0.008295 | −0.3 | 0.76624 |
| BMI | 0.009303 | 0.00555 | 1.676 | 0.10345 |
| Diabetes with respect to “Yes” | −0.096071 | 0.051379 | −1.87 | 0.07068 |
| Depression (with respect to “Yes”) | 0.017801 | 0.048754 | 0.365 | 0.71742 |
| Tobacco Abuse (with respect to “Yes”) | −0.06144 | 0.044716 | −1.374 | 0.17898 |
| APOE | 0.057165 | 0.039934 | 1.431 | 0.16199 |
| OGG1 | −0.024474 | 0.036719 | −0.667 | 0.50986 |
| R-squared | 0.4417 | p-value | 0.2672 | |
| Adjusted R-squared | 0.2672 | df | 10 and 32 | |
| F-statistic | 2.532 | Sample n | 43 |
Multiple linear regression models for 8oxoG “hotspots” in each population were performed and no associations were observed in the MA population; however, in the NHW population a significant negative association to age was discerned (Supplementary Tables 27–28). Although the significant association to age in the NHW population was previously observed in the non-“hotspot” stratified regression model, generally the “hotspot” stratified analyses were less informative.
Discussion
Ethnic/racial differences in developing cognitive impairment are known to exist, yet reports investigating biological, behavioral, and lifestyle factors that lead to differential mechanisms of neurodegeneration in populations more heavily burdened by cognitive decline are limited. Here, we investigated the predictability of 8oxoG variant count from two blood fractions in assessing risk for cognitive decline in two populations. Additionally, haplogroup-specific associations to ccf-mtDNA 8oxoG variants were performed. We hypothesized that indirectly evaluating mitochondrial dysfunction through cellular mitochondrial 8oxoG sSNVs may serve as a better biomarker for MAs due to their observed metabolic endophenotype and burden, while ccf-mtDNA 8oxoG variants may provide improved utility as a biomarker for NHWs due to their inflammatory endophenotype.
Altogether, our results confirm MAs, especially females, show greater mtDNA oxidative damage compared to NHWs. Tobacco abuse trended for significance with increasing cellular 8oxoG mutational load in MAs; however, interestingly, non-depressed individuals showed elevated cellular 8oxoG variant burden. Stratified regression analysis by population in buffy coat PBMCs demonstrated an association with AD, sex, education, and tobacco abuse, while this was not observed in NHWs. Similarly, ccf-8oxoG variant load was significantly higher in MAs, and MA females had elevated levels compared to males. Ccf-8oxoG stratified regression analysis for NHWs showed a suggestive association with normal cognition in younger aged males without diabetes. This may indicate that oxidative variants from ccf-mtDNA are reduced in older NHW females with AD and diabetes comorbidity; however, the potential reason for this is unclear. There is growing evidence indicating the protective effects of estrogen against OS related damage42,43. Estrogen deficiency post menopause is associated with increased levels of OS, higher blood levels of free fatty acids, and reduced antioxidant defense42,43, so it is expected that aging females would demonstrate elevated levels of oxidative damage. Nonetheless, due to our observation it begs the question if there are sex-related differences for the age-related decline in mitophagy.
Depression is a known risk factor for developing MCI and AD, and a study demonstrated a depressive endophenotype of MCI and AD in MAs44. Furthermore, numerous studies report MAs experience more depressive symptoms compared to other Hispanic/Latino subpopulations45,46, as well as NHWs47–52. Accumulating evidence indicates that individuals with depression have higher levels of 8oxoG and oxidative damage, as OS encompasses a critical role in depression pathophysiology through the activity of ROS53,54. Substantial evidence indicates a higher prevalence of depression and depressive symptoms among MAs, yet our data denoted that non-depressed MAs exhibited elevated levels of 8oxoG variants in buffy coat PBMCs. However, depression appeared to be underrepresented because of limited reports of depression in MAs with MCI and AD. Subsequent regression models in the whole cohort and MA population show a negative trend between 8oxoG variant count in buffy PBMCs and non-depressed MAs. Surveying for the presence or absence of depression may have poor resolution when investigating cognitive associations compared to assessing for a collection of depressive symptoms. Previous studies report distinct clustering of depressive symptoms is imperative when studying the connection between cognition and depression55,56. Our results for 8oxoG and depression among MAs warrants further investigation by implementing depressive symptoms and/or other indicators of depression.
Our results revealed increased levels of 8oxoG variants in buffy PMBCs of MAs with a history of tobacco abuse. Smoking tobacco and exposure to tobacco smoke has been shown to cause elevated levels of 8oxoG compared to non-smokers57–60 because of the various carcinogens contained within61,62. As previously mentioned, carcinogens readily form DNA adducts and can lead to OS through the production of ROS. Additionally, cigarette smoke has been recognized to cause chronic inflammation leading to increasing OS which further results in accumulating oxidative damage61,63. A recent study reported that smoking tobacco increased risk for cognitive decline in aging MAs64. Following linear regression models including MAs all demonstrated a significant link with tobacco abuse. These results seem to indicate tobacco abuse as a strong modifiable risk factor for increased mitochondrial oxidative damage in MAs and demonstrates the importance of addressing such behaviors to prevent increased risk for CI in this population.
Our higher resolution linear regression models in the whole cohort from buffy coat PBMCs established that population (MA), tobacco abuse, BMI, education, and population × sex were statistically associated with 8oxoG somatic variants. AD was suggestively associated with cellular 8oxoG sSNVs when assessing an interaction between diabetes and cognitive status. These results were not observed in the NHW population, and perhaps of interest is the fact that many of the coefficients were in the opposite direction (though not significant). Increasing evidence connects AD and T2D, showing a greater risk for cognitive decline due to T2D, and robust correlations indicate high blood sugar is associated with the presence of Ab plaques65. Brain dysfunction is frequently observed in earlier stages of T2D, and hemoglobin A1C (established biomarker for T2D) has been related to decline in functional memory and hippocampal size65. Links between T2D and AD implicate mitochondrial dysfunction as a participating factor in the development and/or progression of neurodegeneration and may be of exceptional importance for ethnic/racial differences in disease severity and manifestation. This evidence further suggests that mitochondrial health could be a contributor to the unexplained disparities in CI among MAs, especially since MAs are at great risk for metabolic disorders.
It is important to note that this study has its limitations including (1) measuring 8oxoG lesions indirectly, (2) small sampling for the plasma dataset, (3) lacking biochemical, metabolic, and inflammatory phenotypes, (4) missing most nDNA variants, (5) solely sampling blood tissue, (6) evaluating in one cohort, and (7) APOE in the NHW model could have reduced power due to a larger number of missingness compared to MAs. To better understand the biological and mechanistic roles of mitochondrial dysfunction and oxidative DNA damage in this context, future studies should incorporate larger sampling, include more biological markers indicative of metabolic health and systemic inflammation, determine if utilizing MMSE, CDR sum, and/or other neuropsychological tests for cognitive function strengthens our power to further support/validate our results, and characterize the nuclear genetic background associated with the mtDNA for each subject. Future studies should also investigate the mechanistic role of mitochondrial processes, such as mitophagy and mitochondrial quality control and sensing, play in contributing to the observed differences in cellular and ccf-mtDNA 8oxoG sSNVs between MAs and NHWs in relation to cognitive decline. Additionally, future studies will aim to validate the applicability of peripheral cellular and cell-free pathophysiological phenotypes as biomarkers for assessing brain pathology, disease risk, and/or disease stage. These studies will also investigate expression of DNA repair machinery, the role of sex hormones, and validate oxidative mtDNA load using alternative methods.
Uniquely, our data specifically point to novel, population-based effects in 8oxoG damage in cellular and cell-free mtDNA. Overall, our results indicate both cellular and ccf-8oxoG variants mtDNA are significantly elevated in MAs compared to NHWs and indicate sex-differences (Fig. 5). Notably, our results from evaluating oxidized cellular mtDNA compared to ccf-mtDNA presents the possibility that these biomarkers may have significant predictive capability in MAs, especially females, compared to NHWs due to the observed statistical significance of assessing various independent variables. This evidence implies mitochondrial dysfunction in cellular mtDNA may be distinctly related to disease pathology in MAs with cognitive decline, whereas in ccf-mtDNA displayed poor associations in MAs compared to NHWs. This cumulative evidence supports the notion that (1) blood-based signatures of mitochondrial dysfunction differ between ethnic/racial populations, (2) cellular and ccf-mtDNA possess different functionality in potentially developing pathophysiological conditions, and (3) ethnic/racial differences exist in the manifestation of neurodegeneration through the assessment of mitochondrial oxidative DNA damage from different blood fractions.
Figure 5.
Hypothetical schematic representing the potential mechanism(s) observed from cellular and ccf-mtDNA 8oxoG variants in MA vs NHW participants of TARCC. In the buffy coat PBMC blood fraction (left) observations in cellular 8oxoG variant count were found to be significant in MAs and the effects were not observed in NHWs. In buffy coat PBMCs, cellular 8oxoG variant count was significantly elevated in MAs, especially females, and was associated with CI and tobacco abuse. Modifiable risk factors, biological processes, and genetics such as lifestyle, environment, social determinants of health, immune cell function, and mito-nuclear interactions are theorized to contribute to elevated oxidative damage to mtDNA in MAs from TARCC. In the blood plasma fraction (right) observations of ccf-8oxoG variant count were significantly reduced in NHW females and were associated with AD and diabetes. These results suggest possible alterations in mitochondrial quality control and/or lack of sensing in NHW females. Overall results from cellular and ccf-mtDNA 8oxoG variant loads suggest mitophagy may play a role in ethnic/racial differences in AD etiology. This figure was created with BioRender.com.
Methods
Sample Acquisition and Description
Cohort:
The Texas Alzheimer’s Research and Care Consortium (TARCC) is a population-based collaborative longitudinal research initiative that has expanded between several Texas medical research institutions66. TARCC explores factors that may attribute to the development and progression of cognitive impairment due to AD in the MA population compared to their NHW counterparts.
Participants:
The study received institutional review board approval under the University of North Texas Health Science Center IRB #1330309–1 and all experiments were performed in accordance with relevant guidelines and regulations. Informed written consent was obtained from participants and/or their legally authorized proxies to take part in the study and allow publication of findings before data collection. Volunteer aging participants enrolled in TARCC annually complete a medical evaluation, clinical interview, neuropsychological testing, and blood draw. Eligible participants obtained categorical clinical diagnoses of ‘Alzheimer’s disease’, ‘Mild Cognitive Impairment’, and ‘Normal Control’ based on the criteria provided by the National Institute for Neurological Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association67. Additional information regarding the inclusion and exclusionary criteria of TARCC has been discussed elsewhere44. This study included NHW and MA subjects (N = 559; Table 1) diagnosed with Alzheimer’s Disease (n = 104), Mild Cognitive Impairment (n = 127), or normal cognition (n = 328). Obtained buffy coat samples from NHWs (n = 261) and MAs (n = 299) and a subset of plasma samples from 62 NHWs and 57 MAs (N = 119; Table 4) collected at the same visit were selected to match the distribution of subjects with respect to age, sex, and type-2 diabetes among both populations. The plasma subset did not include individuals diagnosed with MCI. These samples were analyzed to characterize cellular and circulating cell-free mtDNA (ccf-mtDNA) oxidative damage from blood.
Measurement of mtDNA Mutational Load from Buffy Coat and Plasma
DNA Extraction:
DNA from both the buffy coat and plasma was extracted individually from 200 mL of each sample using the Mag-Bind Blood & Tissue DNA HDQ 96 kit (Omega Bio-tek, Norcross, GA). Buffy coat and plasma DNA extractions were conducted using the Hamilton Microlab STARlet automated liquid handler (Hamilton Company, Reno, NV) and manually, respectively.
Whole mtDNA amplification:
The whole mitochondrial genome and large mtDNA fragments for each sample were amplified using the REPLI-g Human Mitochondrial DNA kit (Qiagen, Venlo, Netherlands) following the manufacturer’s protocol. This kit uses the high fidelity proofreading phi29 DNA polymerase capable of both rolling circle and multiple displacement amplification in combination of random hexamers68. Mitochondrial genome amplification was performed in order to increase mtDNA levels relative to nuclear DNA to enhance mtDNA coverage for whole genome sequencing. Amplified product was quantified via Qubit dsDNA BR assay on the Qubit 4 fluorometer (Invitrogen™, Thermo Fisher Scientific, Waltham, MA) for each sample and a small test size of approximately 12 samples were evaluated to determine the distribution of amplicon sizes using the 4200 TapeStation System (Agilent Technologies, Santa Clara, CA) following the manufacturer’s protocol. The Genomic DNA ScreenTape and corresponding reagents were used to determine the presence of mtDNA fragments from 200 bp to the whole genome.
mtDNA Sequencing:
The Nextera XT™ DNA Library Preparation kit (Illumina, San Diego, CA) was used to prepare the sample library for sequencing following the manufacturer’s protocol. All samples were sequenced on the NextSeq 550 Sequencer (Illumina) platform with high output kit v2.5 generating paired-end reads of 150bp for 300 cycles. The buffy coat samples had an average read depth of 1855X, while the plasma samples had an average read depth of 3970X.
Sequence Mapping/Alignment and Variant Calling:
Raw mtDNA gzipped FASTQ pairs generated for each sample were aligned to the reference genome hg38 via BWA-MEM69 (v0.7.17) using the default parameter for mapping to generate SAM files. Post-alignment SAM files were processed with SAMtools (v.1.9) to produce BAM files that were subsequently sorted, indexed, and statistically assessed by coordinate70. Resultant processed aligned sequence reads within the BAM files were assigned to a single new read-group through the Picard tool “AddOrReplaceReadGroups”71. Duplicate reads resulting from sample preparation, or the sequencing instrument were removed from each sample single new read-group BAM file with the GATK4 Spark application of the Picard tool “MarkDuplicates”72. The BAM files were then indexed with SAMtools (v.1.9)70 and used for somatic variant calling including low allelic fractions and excluding read orientation base qualities (Phred score) under 30. High-depth mitochondrial somatic variants were called via the GATK4 variant caller, Mutect2, utilizing the mitochondria mode72,73.
Oxidation Artifact Assessment:
Picard tool, CollectOxoGMetrics, was used to calculate Phred-scaled probability scores for basecalls to differentiate biological alternative basecalls from technical oxidative damage due to 8oxoG (http://broadinstitute.github.io/picard). Readers are encouraged to review the study reported by Costello et al., for a comprehensive analysis of Next Generation Sequencing 8oxoG artifact generation and detection74. A text file was generated for each sample and were subjected to manual review to exclude technical oxidative artifacts with a Phred score below 30.
Identification of Variants Indicative of Oxidative Damage:
The variant call files were manually assessed to identify 8oxoG transversions within the mitochondrial genome. The process of identifying these specific oxidative transversions has been previously described19. Variants indicative of 8oxoG damage for each subject from the buffy coat portion were summed and normalized by accounting for read depth (variant count per 1000 read depth) to evaluate group differences based on the following variables: population, cognition, sex, type-2 diabetes, comorbidity (cognitive impairment and diabetes), both APOE and OGG1 genotype, and lifestyle factors. Variants indicative of 8oxoG damage from plasma was summed and normalized by accounting for read depth and were log10 transformed to evaluate group differences with the same variables described above. 8oxoG variant “hotspots” were identified as variant locations with at least 25 participants in the cohort observed.
APOE and OGG1 Genotyping Imputation:
Genome-wide SNP profiles were generated using the Illumina Infinium Multi-Ethnic Global Array which types 1.7 million SNPs. Standard filtering based on SNP missingness, individual missingness, and minor allele frequency (5%) was conducted according to Anderson et al., 201075. Genetic imputation of APOE (rs7412 and rs429358 for individuals missing APOE genotypes) and OGG1 (rs1052133) was performed using Impute2 based on the 1000 Genomes Project Phase 3 data; probabilistic genotypes for were called at a threshold of 0.8.
Statistical Analyses:
Statistical analyses were performed using Microsoft Excel, IBM SPSS software (v. 27.0), R software (v. 4.2.0), and GraphPad Prism software (v. 9.4.0). Welch’s t-test (two-tailed) and two-way ANOVA were performed on 8oxoG mutational load to compare between both population groups. Multiple linear regression analysis was performed to evaluate the relationship between cognition, sex, age, education, diabetes and depression status, and tobacco abuse with 8oxoG variant count both within the whole study cohort and in stratified analyses of MAs and NHWs.
Acknowledgments
We thank Nicole Hales (currently at 10X Genomics) for library preparation and sequencing of the buffy coat samples. We thank Viviana Mancilla (currently at Eppendorf) for library preparation and sequencing of the plasma samples. Research reported in the publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R25GM125587, the National Institutes on Minority Health and Health Disparities of the National Institutes of Health under Award Number U54MD006882, and by the Cancer Prevention and Research Institute of Texas (CPRIT) under Award Number RP210046. Dr. Thorpe was supported by the National Institutes on Minority Health and Health Disparities of the National Institutes of Health under Award Number U54MD000214 and the National Institutes on Aging under Award number P30AG059298. This study was made possible by the Texas Alzheimer’s Research and Care Consortium (TARCC) funded by the state of Texas through the Texas Council on Alzheimer’s Disease and Related Disorders. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Footnotes
Competing Interests
The authors declare no competing financial or non-financial interests.
Contributor Information
Danielle Marie Reid, University of North Texas Health Science Center.
Robert C. Barber, University of North Texas Health Science Center
Harlan P. Jones, University of North Texas Health Science Center
Roland J. Thorpe, Johns Hopkins Center for Health Disparities Solutions, Johns Hopkins Bloomberg School of Public Health
Jie Sun, University of North Texas Health Science Center.
Zhengyang Zhou, University of North Texas Health Science Center.
Nicole R. Phillips, University of North Texas Health Science Center
Data Availability Statement
The oxidative damage datasets generated during the current study are available at in the Synapse data repository under project ID syn26410406 (“mtDNA_8oxoG_NGSstudy”, https://doi.org/10.7303/syn26410406).
References
- 1.2022 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia 18, 700–789 (2022). [DOI] [PubMed] [Google Scholar]
- 2.Verri M. et al. Mitochondrial Alterations, Oxidative Stress and Neuroinflammation in Alzheimer’s Disease. Int J Immunopathol Pharmacol 25, 345–353 (2012). [DOI] [PubMed] [Google Scholar]
- 3.Chen Z. & Zhong C. Oxidative stress in Alzheimer’s disease. Neurosci Bull 30, 271–281 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Jun G. Meta-analysis Confirms CR1, CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals Interactions With APOE Genotypes. Arch Neurol 67, 1473 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.O’Bryant S. E. et al. Biomarkers of Alzheimer’s Disease Among Mexican Americans. Journal of Alzheimer’s Disease 34, 841–849 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.O’Bryant S. E. et al. Decreased C-reactive protein levels in Alzheimer disease. J Geriatr Psychiatry Neurol 23, 49–53 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.O’Bryant S. E. et al. A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 67, 1077–81 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Gamba P. et al. Oxidized cholesterol as the driving force behind the development of Alzheimer’s disease. Front Aging Neurosci 7, (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Wu S., Vega W. A., Resendez J. & Jin H. Latinos and Alzheimer’s Disease: New Numbers Behind the Crisis. https://www.usagainstalzheimers.org/sites/default/files/Latinos-and-AD_USC_UsA2-Impact-Report.pdf (2016).
- 10.Kershaw R. M. & Hodges N. J. Repair of oxidative DNA damage is delayed in the Ser326Cys polymorphic variant of the base excision repair protein OGG1. Mutagenesis 27, 501–510 (2012). [DOI] [PubMed] [Google Scholar]
- 11.Komakula S. S. B. et al. The DNA Repair Protein OGG1 Protects Against Obesity by Altering Mitochondrial Energetics in White Adipose Tissue. Sci Rep 8, 14886 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Sampath H. et al. 8-Oxoguanine DNA Glycosylase (OGG1) Deficiency Increases Susceptibility to Obesity and Metabolic Dysfunction. PLoS One 7, e51697 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Thameem F. et al. The Ser(326)Cys Polymorphism of 8-Oxoguanine Glycosylase 1 (OGG1) Is Associated with Type 2 Diabetes in Mexican Americans. Hum Hered 70, 97–101 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Mootha V. K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34, 267–273 (2003). [DOI] [PubMed] [Google Scholar]
- 15.Patti M. E. et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proceedings of the National Academy of Sciences 100, 8466–8471 (2003). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Zilliox L. A., Chadrasekaran K., Kwan J. Y. & Russell J. W. Diabetes and Cognitive Impairment. Curr Diab Rep 16, 87 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Mayeda E. R., Haan M. N., Kanaya A. M., Yaffe K. & Neuhaus J. Type 2 Diabetes and 10-Year Risk of Dementia and Cognitive Impairment Among Older Mexican Americans. Diabetes Care 36, 2600–2606 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Silzer T. et al. Circulating mitochondrial DNA: New indices of type 2 diabetes-related cognitive impairment in Mexican Americans. PLoS One 14, e0213527 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Reid D. M. et al. Mitochondrial DNA oxidative mutations are elevated in Mexican American women potentially implicating Alzheimer’s disease. npj Aging 8, (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Cooke M. S., Evans M. D., Dizdaroglu M. & Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. The FASEB Journal 17, 1195–1214 (2003). [DOI] [PubMed] [Google Scholar]
- 21.Liguori I. et al. Oxidative stress, aging, and diseases. Clin Interv Aging Volume 13, 757–772 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Wu L. L., Chiou C.-C., Chang P.-Y. & Wu J. T. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clinica Chimica Acta 339, 1–9 (2004). [DOI] [PubMed] [Google Scholar]
- 23.Wang X. et al. Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1842, 1240–1247 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Cadet J., Douki T. & Ravanat J.-L. Measurement of oxidatively generated base damage in cellular DNA. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 711, 3–12 (2011). [DOI] [PubMed] [Google Scholar]
- 25.Kino K., Hirao-Suzuki M., Morikawa M., Sakaga A. & Miyazawa H. Generation, repair and replication of guanine oxidation products. Genes and Environment 39, 21 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Poetsch A. R. The genomics of oxidative DNA damage, repair, and resulting mutagenesis. Comput Struct Biotechnol J 18, 207–219 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Loft S. et al. Biomarkers of oxidative damage to DNA and repair. Biochem Soc Trans 36, 1071–1076 (2008). [DOI] [PubMed] [Google Scholar]
- 28.Tatsuta T. & Langer T. Quality control of mitochondria: protection against neurodegeneration and ageing. EMBO J 27, 306–14 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Lovell M. A. & Markesbery W. R. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer’s disease. Nucleic Acids Res 35, 7497–7504 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Mao P. & Reddy P. H. Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer’s disease: Implications for early intervention and therapeutics. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1812, 1359–1370 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Peña-Bautista C. et al. Oxidative Damage of DNA as Early Marker of Alzheimer’s Disease. Int J Mol Sci 20, 6136 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Miller M. B. et al. Somatic genomic changes in single Alzheimer’s disease neurons. Nature 604, 714–722 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Clay Montier L. L., Deng J. J. & Bai Y. Number matters: control of mammalian mitochondrial DNA copy number. Journal of Genetics and Genomics 36, 125–131 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Jeong H. et al. Peripheral biomarkers of mitochondrial dysfunction in adolescents with bipolar disorder. J Psychiatr Res 123, 187–193 (2020). [DOI] [PubMed] [Google Scholar]
- 35.Gambardella S. et al. ccf-mtDNA as a Potential Link Between the Brain and Immune System in Neuro-Immunological Disorders. Front Immunol 10, (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Boyapati R. K., Tamborska A., Dorward D. A. & Ho G.-T. Advances in the understanding of mitochondrial DNA as a pathogenic factor in inflammatory diseases. F1000Res 6, 169 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Trifunov S. et al. Circulating Cell-Free Mitochondrial DNA in Cerebrospinal Fluid as a Biomarker for Mitochondrial Diseases. Clin Chem 67, 1113–1121 (2021). [DOI] [PubMed] [Google Scholar]
- 38.Duvvuri B. & Lood C. Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases. Front Immunol 10, (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Polina I. A., Ilatovskaya D. v. & DeLeon-Pennell K. Y. Cell free DNA as a diagnostic and prognostic marker for cardiovascular diseases. Clinica Chimica Acta 503, 145–150 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Szilágyi M. et al. Circulating Cell-Free Nucleic Acids: Main Characteristics and Clinical Application. Int J Mol Sci 21, 6827 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Kaur U. et al. Reactive oxygen species, redox signaling and neuroinflammation in Alzheimer’s disease: the NF-κB connection. Curr Top Med Chem 15, 446–457 (2015). [DOI] [PubMed] [Google Scholar]
- 42.Sekhon L. H. & Agarwal A. The Menopause and Oxidative Stress. in Studies on Women’s Health (eds. Agarwal A., Aziz N. & Rizk B.) 181–203 (Humana Press, 2013). doi: 10.1007/978-1-62703-041-0_11. [DOI] [Google Scholar]
- 43.Ventura-Clapier R. et al. Mitochondria: a central target for sex differences in pathologies. Clin Sci 131, 803–822 (2017). [DOI] [PubMed] [Google Scholar]
- 44.Johnson L. A., Hall J. R. & O’Bryant S. E. A Depressive Endophenotype of Mild Cognitive Impairment and Alzheimer’s Disease. PLoS One 8, e68848 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Camacho Á. et al. Anxious-depression among Hispanic/Latinos from different backgrounds: results from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Soc Psychiatry Psychiatr Epidemiol 50, 1669–1677 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Hooker K. et al. Depression Among Older Adults in the United States by Disaggregated Race and Ethnicity. Gerontologist 59, 886–891 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Johnson L. A. et al. Depression, inflammation, and memory loss among Mexican Americans: analysis of the HABLE cohort. Int Psychogeriatr 29, 1693–1699 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.O’Bryant S. E. et al. Risk factors for mild cognitive impairment among Mexican Americans. Alzheimer’s & Dementia 9, 622 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Gonzalez H. M., Haan M. N. & Hinton L. Acculturation and the Prevalence of Depression in Older Mexican Americans: Baseline Results of the Sacramento Area Latino Study on Aging. J Am Geriatr Soc 49, 948–953 (2001). [DOI] [PubMed] [Google Scholar]
- 50.de Oliveira G., Cianelli R., Gattamorta K., Kowalski N. & Peragallo N. Social Determinants of Depression Among Hispanic Women. J Am Psychiatr Nurses Assoc 23, 28–36 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Diniz B. S., Fisher-Hoch S. & McCormick J. The association between insulin resistance, metabolic variables, and depressive symptoms in Mexican-American elderly: A population-based study. Int J Geriatr Psychiatry 33, e294–e299 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.O’Bryant S. E., Humphreys J. D., Schiffer R. B. & Sutker P. B. Presentation of Mexican Americans to a Memory Disorder Clinic. J Psychopathol Behav Assess 29, 137–140 (2007). [Google Scholar]
- 53.Ceylan D. et al. Alterations in levels of 8-Oxo-2’-deoxyguanosine and 8-Oxoguanine DNA glycosylase 1 during a current episode and after remission in unipolar and bipolar depression. Psychoneuroendocrinology 114, 104600 (2020). [DOI] [PubMed] [Google Scholar]
- 54.Vaváková M., Ďuračková Z. & Trebatická J. Markers of Oxidative Stress and Neuroprogression in Depression Disorder. Oxid Med Cell Longev 2015, 1–12 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Hall J. et al. Higher Groundwater Selenium Exposure Is Associated with Better Memory: A Project FRONTIER Study. Neurosci Med 03, 18–25 (2012). [Google Scholar]
- 56.Ivnik R. J. et al. Mayo’s older americans normative studies: WAIS-R norms for ages 56 to 97. Clinical Neuropsychologist 6, 1–30 (1992). [Google Scholar]
- 57.Asami S. Cigarette smoking induces an increase in oxidative DNA damage, 8-hydroxydeoxyguanosine, in a central site of the human lung. Carcinogenesis 18, 1763–1766 (1997). [DOI] [PubMed] [Google Scholar]
- 58.Romano G. et al. Evaluation of 8-hydroxydeoxyguanosine in human oral cells: the importance of tobacco smoke and urban environment. Anticancer Res 20, 3801–5 (2000). [PubMed] [Google Scholar]
- 59.Mesaros C., Arora J. S., Wholer A., Vachani A. & Blair I. A. 8-Oxo-2′-deoxyguanosine as a biomarker of tobacco-smoking-induced oxidative stress. Free Radic Biol Med 53, 610–617 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Lodovici M. et al. Active and Passive Smoking and Lifestyle Determinants of 8-Oxo-7,8-Dihydro-2′-Deoxyguanosine Levels in Human Leukocyte DNA. Cancer Epidemiology, Biomarkers & Prevention 14, 2975–2977 (2005). [DOI] [PubMed] [Google Scholar]
- 61.Caliri A. W., Tommasi S. & Besaratinia A. Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer. Mutat Res Rev Mutat Res 787, 108365 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Wiencke J. K. DNA adduct burden and tobacco carcinogenesis. Oncogene 21, 7376–7391 (2002). [DOI] [PubMed] [Google Scholar]
- 63.Saetta M. Airway Inflammation in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 160, S17–S20 (1999). [DOI] [PubMed] [Google Scholar]
- 64.Collins N., Sachs-Ericsson N., Preacher K. J., Sheffield K. M. & Markides K. Smoking Increases Risk for Cognitive Decline Among Community-Dwelling Older Mexican Americans. The American Journal of Geriatric Psychiatry 17, 934–942 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Alzheimer’s Association. Diabetes and cognitive decline. (2021). [Google Scholar]
- 66.Waring S. et al. The Texas Alzheimer’s Research Consortium longitudinal research cohort: study design and baseline characteristics. Tex Public Health J 60, 9–13 (2008). [Google Scholar]
- 67.McKhann G. et al. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34, 939–939 (1984). [DOI] [PubMed] [Google Scholar]
- 68.Qiagen. REPLI-g Mitochondrial DNA Kit. https://www.qiagen.com/us/products/discovery-and-translational-research/pcr-qpcr-dpcr/preamplication/repli-g/repli-g-mitochondrial-dna-kit/.
- 69.Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. (2013). [Google Scholar]
- 70.Danecek P. et al. Twelve years of SAMtools and BCFtools. Gigascience 10, (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Toolkit Picard. Broad Institute https://broadinstitute.github.io/picard/ (2019). [Google Scholar]
- 72.van der Auwera G. A. & O’Connor B. D. Genomics in the Cloud. (O’Reilly Media, Inc., 2020). [Google Scholar]
- 73.Benjamin D. et al. Calling Somatic SNVs and Indels with Mutect2. bioRxiv 861054 (2019) doi: 10.1101/861054. [DOI] [Google Scholar]
- 74.Costello M. et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res 41, e67–e67 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Anderson C. A. et al. Data quality control in genetic case-control association studies. Nat Protoc 5, 1564–1573 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The oxidative damage datasets generated during the current study are available at in the Synapse data repository under project ID syn26410406 (“mtDNA_8oxoG_NGSstudy”, https://doi.org/10.7303/syn26410406).




